stockrowICON PLC
ICLR Healthcare Diagnostics & Research
ICON PLC’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.76% from fiscal 2024.
- Revenue
- −2.86%
- EPS
- +143.2%
- Free cash flow
- −8.01%
- Total debt
- −0.86%
Quarter to September 2026, against a year earlier
Follow ICLR
Alert me
ICON PLC (ICLR) Revenue growth
ICON PLC's revenue growth over the twelve months to 30 September 2026 was 1.82%, up 1.1 percentage points from fiscal 2025 (0.76%). Over the past ten years it has ranged from −0.30% (fiscal 2020) to 95.9% (fiscal 2021); the current reading is higher than 18% of that period. That is below the Diagnostics & Research industry median of 8.99% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 0.76% | (0.09) |
| FY2024 | 0.85% | (4.04) |
| FY2023 | 4.89% | (36.35) |
| FY2022 | 41.2% | (54.69) |
| FY2021 | 95.9% | 96.23 |
| FY2020 | −0.30% | (8.39) |
| FY2019 | 8.09% | (39.53) |
| FY2018 | 47.6% | 42.10 |
| FY2017 | 5.52% | (0.29) |
| FY2016 | 5.81% | 1.04 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | −2.86% | (4.06) |
| Jun 2026 | 1.20% | 0.27 |
| Mar 2026 | 0.93% | (7.49) |
| Dec 2025 | 8.42% | 5.74 |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| GH Guardant Health, Inc. compare | 41.7% |
| MEDP Medpace Holdings, Inc. compare | 20.4% |
| DGX Quest Diagnostics Incorporated compare | 9.13% |
| LH Labcorp Holdings Inc. compare | 6.02% |
| ILMN Illumina, Inc. compare | 5.83% |
| RVTY Revvity Inc. compare | 4.56% |
| QGEN QIAGEN N.V. compare | 2.96% |
| ICLR ICON PLC | 1.82% |
| CRL Charles River Laboratories International, Inc. compare | −1.16% |
| Diagnostics & Research industry median | 8.99% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on ICLR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement